<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115353</article-id><article-id pub-id-type="publisher-id">ACM-42780</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_92012478.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童MOG抗体相关疾病9例临床病例分析
  Analysis of 9 Clinical Cases of Children with MOG Antibody-Associated Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>梦菲</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>青岛大学附属医院神经内分泌儿科，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2449</fpage><lpage>2455</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨儿童髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)的临床特征。方法：收集青岛大学附属医院2018年1月至2020年12月收集的9例MOGAD儿童患者，对他们的临床症状、临床表型、实验室检查、MRI表现、治疗措施及疗效、复发及预后情况进行总结分析。结果：9例患儿平均发病年龄5.78 &#177; 2.73岁，男女比例5:4。临床表型主要有ADEM (5/9)、NMOSD (2/9)、ON (1/9)和脑炎(1/9)。ADEM患儿症状主要有头晕(3/5)、嗜睡(3/5)、头痛(2/5)、癫痫发作(2/5)，ON的患儿表现为视物模糊、眼痛。所有患儿均未出现抗NMDAR抗体重叠。9例患儿颅脑MRI中额叶、顶叶、颞叶等所有脑叶均可受累，以皮层下白质、深部灰质为主，4例患儿皮层受累，ON、NMOSD患儿中2例出现视神经(视交叉前)信号异常，另1例则为楔回、视辐射受累。1例患儿颈髓受累，1例MRI检查正常。8例患儿均采用大剂量静脉内输注丙种球蛋白(IVIG)和甲强龙冲击治疗，1例ON患儿予小剂量糖皮质激素治疗，所有患儿症状均在1周内消失。9例患儿随访时间24.17 &#177; 10.75个月，2例出现复发，复发表型为ADEM，复发后再次用免疫冲击治疗，症状快速消失，且无后遗症状。复查2例复发患儿的血清及脑脊液MOG抗体仍为阳性。结论：MOGAD患儿无明显女性优势，以ADEM为主要表型，MRI检查以皮层下白质最多见。皮层病变与癫痫症状相关。MRI正常不能排除MOGAD。MOGAD对免疫治疗敏感。MOG抗体持续阳性对预测复发病程有提示作用。
   Objective: To explore the clinical features of childhood myelin oligodendrocyte glycoprotein (MOG) antibody-related diseases. Methods: Collect 9 children with MOGAD admitted from the Affiliated Hospital of Qingdao University from January 2018 to December 2020, summarize and analyze their clinical symptoms, clinical phenotypes, laboratory tests, MRI manifestations, treatment measures and efficacy, recurrence and prognosis. Results: The average age of onset was 5.78 years, and the male to female ratio was 5:4. The main clinical phenotypes are ADEM (5/9), NMOSD (2/9), ON (1/9) and encephalitis (1/9). The symptoms of ADEM children mainly include dizziness (3/5), drowsiness (3/5), headache (2/5), and seizures (2/5). Children with ON show blurred vision and eye pain. There was no overlap of anti-NMDAR antibodies in all children. All brain lobes including frontal lobe, parietal lobe and temporal lobe can be affected in 9 children with brain MRI, mainly affected subcortical white matter and deep gray matter. Cortex is affected in four children. Two children with ON and NMOSD had abnormal signals of the optic nerve (pre-optic chiasma), and the other had wedge gyrus and optic radiation involvement. Cervical spinal cord was involved in 1 case, and MRI examination was normal in 1 case. 8 children were treated with high-dose IVIG and methylprednisolone. One child with ON was treated with low-dose glucocorticoids. All the children’s symptoms disappeared within 1 week. The 9 children were followed up for 24.17 &#177; 10.75 months, and 2 cases had recurrence. The recurrence phenotype was ADEM. After the recurrence, immune shock therapy was used again, and the symptoms disappeared quickly without any sequelae. The serum and cerebrospinal fluid MOG antibodies of the 2 relapsed children were still positive. Conclusion: There is no obvious female advantage in children with MOGAD, ADEM is the main phenotype, and subcortical white matter is the most common in MRI examination. Cortical lesions are associated with epilepsy symptoms. A normal MRI cannot exclude MOGAD. MOGAD is sensitive to immunotherapy. Continued positive MOG antibody has a suggestive effect on predicting the course of recurrence.
 
</p></abstract><kwd-group><kwd>MOG抗体相关疾病，细胞转染技术，免疫治疗，复发, MOGAD</kwd><kwd> Cell-Based Assays</kwd><kwd> Immunotherapy</kwd><kwd> Relapse</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨儿童髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)的临床特征。方法：收集青岛大学附属医院2018年1月至2020年12月收集的9例MOGAD儿童患者，对他们的临床症状、临床表型、实验室检查、MRI表现、治疗措施及疗效、复发及预后情况进行总结分析。结果：9例患儿平均发病年龄5.78 &#177; 2.73岁，男女比例5:4。临床表型主要有ADEM (5/9)、NMOSD (2/9)、ON (1/9)和脑炎(1/9)。ADEM患儿症状主要有头晕(3/5)、嗜睡(3/5)、头痛(2/5)、癫痫发作(2/5)，ON的患儿表现为视物模糊、眼痛。所有患儿均未出现抗NMDAR抗体重叠。9例患儿颅脑MRI中额叶、顶叶、颞叶等所有脑叶均可受累，以皮层下白质、深部灰质为主，4例患儿皮层受累，ON、NMOSD患儿中2例出现视神经(视交叉前)信号异常，另1例则为楔回、视辐射受累。1例患儿颈髓受累，1例MRI检查正常。8例患儿均采用大剂量静脉内输注丙种球蛋白(IVIG)和甲强龙冲击治疗，1例ON患儿予小剂量糖皮质激素治疗，所有患儿症状均在1周内消失。9例患儿随访时间24.17 &#177; 10.75个月，2例出现复发，复发表型为ADEM，复发后再次用免疫冲击治疗，症状快速消失，且无后遗症状。复查2例复发患儿的血清及脑脊液MOG抗体仍为阳性。结论：MOGAD患儿无明显女性优势，以ADEM为主要表型，MRI检查以皮层下白质最多见。皮层病变与癫痫症状相关。MRI正常不能排除MOGAD。MOGAD对免疫治疗敏感。MOG抗体持续阳性对预测复发病程有提示作用。</p></sec><sec id="s2"><title>关键词</title><p>MOG抗体相关疾病，细胞转染技术，免疫治疗，复发</p></sec><sec id="s3"><title>Analysis of 9 Clinical Cases of Children with MOG Antibody-Associated Diseases</title><p>Mengfei Peng</p><p>Department of Neuroendocrine Pediatrics, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/62-1572261x4_hanspub.png" /></p><p>Received: Apr. 27<sup>th</sup>, 2021; accepted: May 11<sup>th</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/62-1572261x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the clinical features of childhood myelin oligodendrocyte glycoprotein (MOG) antibody-related diseases. Methods: Collect 9 children with MOGAD admitted from the Affiliated Hospital of Qingdao University from January 2018 to December 2020, summarize and analyze their clinical symptoms, clinical phenotypes, laboratory tests, MRI manifestations, treatment measures and efficacy, recurrence and prognosis. Results: The average age of onset was 5.78 years, and the male to female ratio was 5:4. The main clinical phenotypes are ADEM (5/9), NMOSD (2/9), ON (1/9) and encephalitis (1/9). The symptoms of ADEM children mainly include dizziness (3/5), drowsiness (3/5), headache (2/5), and seizures (2/5). Children with ON show blurred vision and eye pain. There was no overlap of anti-NMDAR antibodies in all children. All brain lobes including frontal lobe, parietal lobe and temporal lobe can be affected in 9 children with brain MRI, mainly affected subcortical white matter and deep gray matter. Cortex is affected in four children. Two children with ON and NMOSD had abnormal signals of the optic nerve (pre-optic chiasma), and the other had wedge gyrus and optic radiation involvement. Cervical spinal cord was involved in 1 case, and MRI examination was normal in 1 case. 8 children were treated with high-dose IVIG and methylprednisolone. One child with ON was treated with low-dose glucocorticoids. All the children’s symptoms disappeared within 1 week. The 9 children were followed up for 24.17 &#177; 10.75 months, and 2 cases had recurrence. The recurrence phenotype was ADEM. After the recurrence, immune shock therapy was used again, and the symptoms disappeared quickly without any sequelae. The serum and cerebrospinal fluid MOG antibodies of the 2 relapsed children were still positive. Conclusion: There is no obvious female advantage in children with MOGAD, ADEM is the main phenotype, and subcortical white matter is the most common in MRI examination. Cortical lesions are associated with epilepsy symptoms. A normal MRI cannot exclude MOGAD. MOGAD is sensitive to immunotherapy. Continued positive MOG antibody has a suggestive effect on predicting the course of recurrence.</p><p>Keywords:MOGAD, Cell-Based Assays, Immunotherapy, Relapse</p><disp-formula id="hanspub.42780-formula64"><graphic xlink:href="//html.hanspub.org/file/62-1572261x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1572261x7_hanspub.png" /> <img src="//html.hanspub.org/file/62-1572261x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>髓鞘少突胶质细胞糖蛋白抗体相关疾病(Myelin oligodendrocyte glycoprotein antibody-associated disorders, MOGAD)是MOG抗体介导的中枢神经系统脱髓鞘疾病，其临床表型多样，包括视神经炎(optic neuritis, ON)、横贯性脊髓炎(transverse myelitis, TM)、视神经脊髓炎谱系疾病(neummyelitis optica spectmm disease, NMOSD)、急性播散性脑脊髓炎(Acute disseminated encephalomyelitis, ADEM)以及一些分类不明确的中枢神经系统获得性脱髓鞘综合征(acquired demyelinating syndromes, ADS) [<xref ref-type="bibr" rid="hanspub.42780-ref1">1</xref>]，另外还有一些罕见表型，例如皮层脑炎 [<xref ref-type="bibr" rid="hanspub.42780-ref2">2</xref>]、脑干脑炎 [<xref ref-type="bibr" rid="hanspub.42780-ref3">3</xref>]、葡萄膜炎 [<xref ref-type="bibr" rid="hanspub.42780-ref4">4</xref>] 等今年来也陆续被发现。MOG抗体相关疾病是一种罕见病，具有年龄依赖性，患病率为每10万人中1.9人，发病率为每10万人中0.1人 [<xref ref-type="bibr" rid="hanspub.42780-ref5">5</xref>]。在1/3的儿童ADS中存在MOG抗体 [<xref ref-type="bibr" rid="hanspub.42780-ref6">6</xref>]。虽然国内外已经发表了MOG抗体相关疾病的诊治共识 [<xref ref-type="bibr" rid="hanspub.42780-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.42780-ref8">8</xref>]，但主要针对青少年和成人，由于MOG抗体相关疾病在儿童中发病率较成人高，迫切需要针对儿童的诊疗标准或共识，因此需要更多的儿童病例支持。本研究收集了青岛大学附属医院2018年1月至2020年12月收集的9例MOG抗体相关疾病儿童患者，对他们的临床症状、临床表型、实验室检查、磁共振(magnetic resonance imaging, MRI)表现、治疗措施及疗效、复发及预后情况进行总结分析，以期对MOG抗体相关疾病的临床诊治提供借鉴。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>研究对象为青岛大学附属医院2018年1月至2020年12月收集的9例MOG抗体相关疾病儿童患者。① 纳入标准：符合2020年发布的《抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病诊断和治疗中国专家共识》 [<xref ref-type="bibr" rid="hanspub.42780-ref9">9</xref>] 中提出的MOGAD诊断标准，但如MRI检查结果正常，则需有脑病、运动障碍等中枢神经系统损伤表现，且血清或脑脊液中MOG抗体阳性。② 排除标准：中枢神经系统感染、神经白塞病、脑胶质瘤、周围神经脱髓鞘疾病等非中枢神经系统ADS疾病以及血清、脑脊液NOG抗体阴性的ADS。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>对9例MOGAD患儿的临床症状、临床表型、实验室检查、MRI表现、治疗措施及疗效、复发及预后情况进行回顾性分析，随访采用门诊随访及电话随访方式。采用细胞转染技术(CBA)检测患儿血清和脑脊液中的MOG抗体，检测前患儿监护人均签署知情同意书。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般情况</title><p>这9例患儿平均发病年龄5.78 &#177; 2.73岁，范围3~12岁，5岁及5岁以下患儿6例，5岁以上患儿3例，男女比例5:4。</p></sec><sec id="s7_2"><title>3.2. 临床症状及临床表型</title><p>9例患儿的临床表型按所占比例大小排列为ADEM (5/9)、NMOSD (2/9)、ON (1/9)和脑炎(1/9)。ADEM患儿的临床症状主要有头晕(3/5)、嗜睡(3/5)、头痛(2/5)、癫痫发作(2/5)的脑病症状，可伴有发热(3/5)、乏力(3/5)、走路不稳(2/5)及面瘫(1/5)症状；NMOSD的2例患儿均有视物模糊、眼痛，其中1例伴有头痛、呕吐；ON的患儿表现为视物模糊、眼痛。</p></sec><sec id="s7_3"><title>3.3. 实验室检查</title><p>对9例患儿进行了血清和脑脊液自身免疫性脑炎抗体[抗N-甲基-D-天冬氨酸受体(anti-NMDA receptor encephalitis receptor, NMDAR)抗体、抗谷氨酸受体(AMPA1型)抗体、抗谷氨酸受体(AMPA2型)抗体、抗富亮氨酸胶质失活蛋白1 (LGI 1)抗体、抗接触蛋白关联蛋白2 (CASP2)抗体、抗GABA B受体抗体]、寡克隆区带(采用等电聚焦点用技术)、抗AQP4抗体IgG、抗髓鞘碱性蛋白(MBP)抗体-IgG、血清呼吸道病原体抗体IgM9项检测，结果均为阴性。</p></sec><sec id="s7_4"><title>3.4. MRI表现</title><p>对9例患儿进行了颅脑、视神经及脊髓MRI检查，按受累部位在患儿中所占比例由高到低排列依次为颞叶(5/9)、额叶(4/9)、基底节区(4/9)、顶叶(3/9)、枕叶(3/9)、小脑(3/9)、丘脑(3/9)、脑桥(3/9)、脑室旁(2/9)、半卵圆中心(2/9)、中脑(1/9)、胼胝体(1/9)，诊断为ON、NMOSD的3例患儿中有2例MRI中出现视神经(视交叉前)信号异常，另1例则为楔回(视觉中枢)、视辐射受累。1例患儿颈髓受累，累及C4-C6节段。除1例患儿MRI检查正常外，余8例患儿均有皮层下白质受累，4例患儿皮层受累。</p></sec><sec id="s7_5"><title>3.5. 治疗措施及疗效</title><p>对于首次起病的治疗，除1例诊断为ON的患儿予小剂量糖皮质激素治疗，余8例患儿均采用大剂量静脉内输注丙种球蛋白(intravenous immunoglobulin, IVIG)1-2g/kg和甲强龙20 mg/kg &#215; 3 d冲击治疗，所有患儿症状均在1周内消失，走路不稳的患儿恢复正常步态，视力下降的患儿从0.2恢复至1.0。</p></sec><sec id="s7_6"><title>3.6. 复发及预后情况</title><p>9例患儿随访时间24.17 &#177; 10.75个月，其中2例出现复发，距首次起病分别间隔21个月和17个月，复发表型为ADEM，复发后再次用IVIG + 甲强龙冲击治疗，患儿症状仍快速消失，且无后遗症状。复查2例复发患儿的血清MOG抗体较首次起病滴度下降，但仍为阳性。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>MOG是一种位于少突胶质细胞和髓鞘表面的糖蛋白，仅存在于中枢神经系统中，确切作用尚不清楚，目前被认为是一种细胞粘附分子、少突胶质细胞微管稳定性的调节因子，并有参与介导补体级联反应的作用 [<xref ref-type="bibr" rid="hanspub.42780-ref10">10</xref>]。MOG是实验性自身免疫性脑脊髓炎(Experimental autoimmune encephalomyelitis, EAE)的重要免疫原 [<xref ref-type="bibr" rid="hanspub.42780-ref11">11</xref>]。由于MOG位于细胞质膜和髓鞘外表面，因此易于与MOG抗体结合，可能的致病机制是嗜神经病毒感染后破坏血脑屏障，使MOG抗原进入外周循环，激活促炎T细胞和MOG特异性B细胞，产生MOG-IgG，并产生白介素(interleukin, IL)-12、IL-23等细胞因子、激活补体，体液免疫和细胞免疫协同作用介导炎性脱髓鞘 [<xref ref-type="bibr" rid="hanspub.42780-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42780-ref13">13</xref>]。早期使用酶联免疫吸附法(Enzyme-linked immunosorbent assay, ELISA)或蛋白质印迹法(westem blots)能在MS、其他中枢神经系统炎性疾病，甚至在在健康人群中也能发现MOG抗体，因为这两种检测方法不能区分与MOG线性表位和构象表位结合的MOG抗体，而只有与构象表位的MOG抗体才具有致病性，因此这两种方法不能反映MOG抗体与脱髓鞘之间的关系 [<xref ref-type="bibr" rid="hanspub.42780-ref11">11</xref>]。目前MOG抗体检测的金标准是细胞转染技术(cell-based assays CBA)，这种方法使用表达于活细胞表面的天然全长的构象性结构完整的人类MOG作为底物，与IgG亚型结合，敏感性和特异性均高。另外四聚体放射免疫法也可用于MOG抗体检测，具有相近的检测效果 [<xref ref-type="bibr" rid="hanspub.42780-ref14">14</xref>]，但由于放射污染等原因应用受到限制。本研究中的MOG抗体即采用CBA方法进行检测。</p><p>由于MOGAD为罕见病，且受时间限制，本研究所收集病例较少，但发现并总结了MOGAD的一些临床特点。既往研究表明， MOGAD与MS和AQP4-IgG阳性的NMOSD相比，女性优势不明显，其临床表型具有年龄依赖性，年长儿以ON、NMOSD为主，而年幼儿以ADEM为主，可能由于生长发育不同阶段免疫系统、中枢神经系统白质及灰质、血脑屏障发育程度不同，导致每个阶段人体对MOG抗体的解剖学易感性不同 [<xref ref-type="bibr" rid="hanspub.42780-ref15">15</xref>]，与本研究相符，本研究中患儿男女比例为5:4，6例5岁以下儿童中有5例ADEM、1例ON，3例5岁以上儿童中有2例为NMOSD、1例脑炎。ADEM及脑炎表型的患儿常出现头晕、嗜睡、头痛、癫痫发作等脑炎表现，而NMOSD、ON患儿则常出现视物模糊、眼痛症状。一项队列研究显示约11.9%的MOGAD患者合并抗NMDA受体抗体 [<xref ref-type="bibr" rid="hanspub.42780-ref16">16</xref>]，临床上表现为抗NMDA受体抗体脑炎典型的精神行为异常、癫痫发作、近事记忆力下降、言语障碍、运动障碍、自主神经功能障碍等，但症状较轻、预后更好，对糖皮质激素及免疫球蛋白治疗反应更好。由于样本量较小，本研究中未发现此现象。</p><p>MOGAD患儿的MRI检查所示颅脑病灶往往边界不清，以皮层下白质、深部灰质受累多见，胼胝体病灶常见，并可出现广泛的“白质营养不良”样病变 [<xref ref-type="bibr" rid="hanspub.42780-ref17">17</xref>]，皮层受累在MOGAD中较AQP4-IgG阳性的NMOSD更为多见 [<xref ref-type="bibr" rid="hanspub.42780-ref18">18</xref>]，且本研究中的4例皮层受累患儿均出现了癫痫症状。本研究中的患儿与此大致相符，以皮层下白质受累为主，深部灰质受累亦多见，约半数患儿皮层受累，并出现丘脑、胼胝体受累。视神经则以双侧受累为主，主要累及前段，眼底检查可见视盘水肿，并可出现视神经周围脂肪组织钆增强 [<xref ref-type="bibr" rid="hanspub.42780-ref19">19</xref>]。本研究中患儿视神经损害为单侧或双侧，2例累及视神经前段，1例累及视辐射及视觉中枢，无视神经周围软组织受累。关于MOGAD的脊髓受累部位目前的临床研究结果中存在矛盾，有的研究认为MOGAD以腰髓和脊髓圆锥受累为主 [<xref ref-type="bibr" rid="hanspub.42780-ref17">17</xref>]，有的研究认为以颈胸段受累为主 [<xref ref-type="bibr" rid="hanspub.42780-ref20">20</xref>]，可能由于此类研究未将成人与儿童患者进行分组，但针对儿童MOGAD的临床研究中均表现为颈胸段受累 [<xref ref-type="bibr" rid="hanspub.42780-ref21">21</xref>]，本研究中即有1例患儿出现颈髓受累。因此，MOGAD在儿童和成人中的表现不同，未来针对儿童的MOGAD诊治共识需要更多的儿童病例支持。</p><p>MOGAD患儿对糖皮质激素及免疫球蛋白治疗敏感 [<xref ref-type="bibr" rid="hanspub.42780-ref22">22</xref>]，本研究中多采用大剂量IVIG + 糖皮质激素冲击治疗，效果显著，经治疗后患儿症状很快消失，但表现为ON的患儿则仅予小剂量糖皮质激素即达到快速恢复的效果。表明针对不同临床表型治疗需个体化，对ON表型患儿免疫冲击治疗或许不是必要手段。</p><p>MOGAD患儿以单相病程多见，也可出现多相病程，包括MDEM、ADEM、ADEM-ON、或NMOSD [<xref ref-type="bibr" rid="hanspub.42780-ref23">23</xref>]。本研究中2例患儿出现复发，距首次起病间隔时间长达21个月。一项国外的研究中1名患者自儿童期开始随访，随访时间长达16年4月，共出现23次复发 [<xref ref-type="bibr" rid="hanspub.42780-ref24">24</xref>]。因此，随着随访时间的延长，复发病程的患儿所占比例可升高。MOG抗体高滴度是疾病处于活动期的表现 [<xref ref-type="bibr" rid="hanspub.42780-ref25">25</xref>]，但MOG抗体水平下降不能作为预测单相病程的指标，但抗体持续阳性可作为预测复发的提示因素 [<xref ref-type="bibr" rid="hanspub.42780-ref26">26</xref>]。本研究中复发的两例患儿在复发病程急性期复查了MOG抗体，显示仍为阳性，但滴度低于首次起病时。</p></sec><sec id="s9"><title>5. 结论</title><p>MOGAD患儿无明显女性优势，以ADEM为主要表型，年长儿以ON、NMOSD为主，MRI检查以皮层下白质最多见，皮层病变为其特点，并与癫痫症状密切相关，MRI正常不能排除MOGAD。MOGAD对免疫冲击治疗敏感，但对ON的治疗需个体化。MOG抗体持续阳性对预测复发病程有提示作用。</p></sec><sec id="s10"><title>6. 展望</title><p>MOGAD是近年来临床研究的热门话题。随着临床病例研究的增多，国内外先后发表了MOGAD的临床诊断和治疗的共识，但并不完全适用于儿童，但MOGAD是儿童中枢神经系统炎性脱髓鞘疾病中最常见的类型，因此迫切需要制定针对儿童的诊疗指南或共识，但需要更多的临床证据支持，尤其是大样本、多中心的临床研究。</p></sec><sec id="s11"><title>文章引用</title><p>彭梦菲. 儿童MOG抗体相关疾病9例临床病例分析Analysis of 9 Clinical Cases of Children with MOG Antibody-Associated Diseases[J]. 临床医学进展, 2021, 11(05): 2449-2455. https://doi.org/10.12677/ACM.2021.115353</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42780-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hou, C., Wu, W., Tian, Y., et al. (2020) Clinical Analysis of Anti-NMDAR Encephalitis Combined with MOG Antibody in Children. Multiple Sclerosis and Related Disorders, 42, Article ID: 102018.  
&lt;br&gt;https://doi.org/10.1016/j.msard.2020.102018</mixed-citation></ref><ref id="hanspub.42780-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ogawa, R., et al. (2017) MOG Antibody—Positive, Benign, Unilateral, Cerebral Cortical Encephalitis with Epilepsy. Neurology—Neuroimmunology Neuroinflammation, 4, e322. &lt;br&gt;https://doi.org/10.1212/NXI.0000000000000322</mixed-citation></ref><ref id="hanspub.42780-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Matesanz, S., Kotch, C., Perrone, C., et al. (2019) Expanding the MOG Phenotype: Brainstem Encephalitis with Punctate and Curvilinear Enhancement. Neurology Neuroimmunology &amp; Neuroinflammation, 6, e619.  
&lt;br&gt;https://doi.org/10.1212/NXI.0000000000000619</mixed-citation></ref><ref id="hanspub.42780-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ramanathan, S., Fraser, C., Curnow, S.R., et al. (2019) Uveitis and Optic Perineuritis in the Context of Myelin Oligodendrocyte Glycoprotein Antibody Seropositivity. European Journal of Neurology, 26, 1137-e75.  
&lt;br&gt;https://doi.org/10.1111/ene.13932</mixed-citation></ref><ref id="hanspub.42780-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sebastian, L., Masoud, M., James, F., et al. (2018) Association of MOG-IgG Serostatus with Relapse after Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurology, 75, 1355-1363.</mixed-citation></ref><ref id="hanspub.42780-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bruijstens, A.L., Lechner, C., Flet, B.L., et al. (2020) E.U. Paediatric MOG Consortium Consensus: Part 1—Classifica- tion of Clinical Phenotypes of Paediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders. European Journal of Paediatric Neurology, 29, 2-13. &lt;br&gt;https://doi.org/10.1016/j.ejpn.2020.10.006</mixed-citation></ref><ref id="hanspub.42780-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">杨坤芳, 陈育才. 儿童多发性硬化和其他中枢神经系统脱髓鞘疾病诊断标准的国际儿童多发性硬化研究小组共识(2012版) [C]//第十三届江浙沪儿科学术会议暨2016年浙江省医学会儿科学学术年会. 湖州: 浙江省医学会儿科学分会、江苏省医学会儿科学分会、上海市医学会儿科学分会: 浙江省科学技术协会, 2016: 2.</mixed-citation></ref><ref id="hanspub.42780-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jarius, S., Paul, F., Aktas, O., et al. (2018) MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing. Journal of Neuroinflammation, 15, 134. &lt;br&gt;https://doi.org/10.1186/s12974-018-1144-2</mixed-citation></ref><ref id="hanspub.42780-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">中国免疫学会神经免疫分会, 邱伟, 徐雁. 抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病诊断和治疗中国专家共识[J]. 中国神经免疫学和神经病学杂志, 2020, 27(2): 86-95.</mixed-citation></ref><ref id="hanspub.42780-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wynford-Thomas, R., Jacob, A. and Tomassini, V. (2019) Neurological Update: MOG Antibody Disease. Journal of Neurology, 266, 1280-1286. &lt;br&gt;https://doi.org/10.1007/s00415-018-9122-2</mixed-citation></ref><ref id="hanspub.42780-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ramanathan, S., Dale, R.C. and Brilot, F. (2016) Anti-MOG Antibody: The History, Clinical Phenotype, and Pathogenicity of a Serum Biomarker for Demyelination. Autoimmunity Reviews, 15, 307-324.  
&lt;br&gt;https://doi.org/10.1016/j.autrev.2015.12.004</mixed-citation></ref><ref id="hanspub.42780-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">董会卿. MOG抗体介导的特发性炎性脱髓鞘疾病[J]. 中国神经免疫学和神经病学杂志, 2017, 24(2): 88-91.</mixed-citation></ref><ref id="hanspub.42780-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">周红雨, 张勤. 髓鞘少突胶质细胞糖蛋白抗体和其他自身免疫抗体并存的临床诊疗涵义[J]. 中华医学杂志, 2020, 100(5): 324-327.</mixed-citation></ref><ref id="hanspub.42780-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">谭建敏. MOG抗体在中枢神经系统炎性脱髓鞘疾病中的诊断价值[J]. 现代医药卫生, 2018, 34(17): 2657-2659.</mixed-citation></ref><ref id="hanspub.42780-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Leite, M.I. and Sato, D.K. (2019) MOG-Antibody-Associated Disease Is Different from MS and NMOSD and Should Be Considered as a Distinct Disease Entity—Yes. Multiple Sclerosis, 26, 272-274.  
&lt;br&gt;https://doi.org/10.1177/1352458519868796</mixed-citation></ref><ref id="hanspub.42780-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fan, S., Xu, Y., Ren, H., et al. (2018) Comparison of Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Disease and AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) When They Co-Exist with Anti-NMDA (N-methyl-D-aspartate) Receptor Encephalitis. Multiple Sclerosis &amp; Related Disorders, 20, 144-152.  
&lt;br&gt;https://doi.org/10.1016/j.msard.2018.01.007</mixed-citation></ref><ref id="hanspub.42780-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Shahriari, M., Yousem, D.M., Sotirchos, E.S., et al. (2020) MOG Antibody Associated Disease: How It Differs from and Resembles Other Neuroinflammatory Disorders. American Journal of Roentgenology, 216, 1031-1039.  
&lt;br&gt;https://doi.org/10.2214/AJR.20.24061</mixed-citation></ref><ref id="hanspub.42780-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C., Liu, C., Fang, L., et al. (2019) Different Magnetic Resonance Imaging Features between MOG Antibody- and AQP4 Antibody-Mediated Disease: A Chinese Cohort Study. Journal of the Neurological Sciences, 405, Article ID: 116430. &lt;br&gt;https://doi.org/10.1016/j.jns.2019.116430</mixed-citation></ref><ref id="hanspub.42780-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tenembaum, S.N. (2021) Pediatric Demyelinating Disease and Anti-MOG Antibody. Clinical and Experimental Neuroimmunology, 12, 5.</mixed-citation></ref><ref id="hanspub.42780-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">周少旦, 付桔, 卜秀群, 等. 17例髓鞘少突胶质细胞糖蛋白抗体相关疾病患者的临床分析[J]. 中风与神经疾病杂志, 2020, 37(12): 1105-1108.</mixed-citation></ref><ref id="hanspub.42780-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">孙红, 谭建敏, 刘静临, 等. 儿童髓鞘少突胶质细胞糖蛋白抗体相关脱髓鞘病57例临床特征及预后分析[J]. 临床儿科杂志, 2020, 38(11): 30-36.</mixed-citation></ref><ref id="hanspub.42780-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">徐敏, 郭虎, 何燕, 等. 儿童髓鞘少突胶质细胞糖蛋白抗体脑脊髓炎13例临床与影像学特征[J]. 中华实用儿科临床杂志, 2019, 34(13): 997-1001.</mixed-citation></ref><ref id="hanspub.42780-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., et al. (2020) Associations of Paediatric Demyelinating and Encephalitic Syndromes with Myelin Oligodendrocyte Glycoprotein Antibodies: A Multicentre Observational Study. The Lancet Neurology, 19, 234-246.</mixed-citation></ref><ref id="hanspub.42780-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Serin, H.M., Yilmaz, S., Simsek, E., et al. (2020) Clinical Spectrum, Treatment and Outcome of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease in Children: A Tertiary Care Experience. Acta Neurologica Belgica, 121, 231-239. &lt;br&gt;https://doi.org/10.1007/s13760-020-01499-9</mixed-citation></ref><ref id="hanspub.42780-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Jia, X., Hui, Y., et al. (2018) Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Demyelination: Comparison between Onset Phenotypes. European Journal of Neurology, 26, 175-183.  
&lt;br&gt;https://doi.org/10.1111/ene.13791</mixed-citation></ref><ref id="hanspub.42780-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Salama, S., Khan, M., Pardo, S., et al. (2019) MOG Antibody-Associated Encephalomyelitis/Encephalitis. Multiple Sclerosis, 25, 1427-1433. &lt;br&gt;https://doi.org/10.1177/1352458519837705</mixed-citation></ref></ref-list></back></article>